DURECT (NASDAQ:DRRX – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $6.91 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
DURECT Stock Performance
NASDAQ DRRX opened at $0.85 on Tuesday. The stock has a market cap of $26.35 million, a PE ratio of -1.39 and a beta of 0.91. DURECT has a 12 month low of $0.70 and a 12 month high of $1.88. The company’s 50-day moving average price is $0.80 and its 200-day moving average price is $1.02.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on shares of DURECT in a research note on Wednesday, March 19th. They issued a “sell” rating on the stock.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Read More
- Five stocks we like better than DURECT
- Conference Calls and Individual Investors
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Low PE Growth Stocks: Unlocking Investment Opportunities
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.
